Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Inhibition of tissue factor signaling suppresses tumor growth

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Versteeg, H. H.
  • Schaffner, F.
  • Kerver, M.
  • Petersen, H. H.
  • Ahamed, J.
  • Felding, Brunhilde
  • Takada, Y.
  • Mueller, B. M.
  • Ruf, Wolfram

publication date

  • January 2008

journal

  • Blood  Journal

abstract

  • Coagulation activation by tissue factor (TF) is implicated in cancer progression, cancer-associated thrombosis and metastasis. The role of direct TF signaling pathways in cancer, however, remains incompletely understood. Here we address how TF contributes to primary tumor growth by using a unique pair of isotype-matched antibodies that inhibit either coagulation (monoclonal antibody [Mab]-5G9) or direct signaling (Mab-10H10). We demonstrate that the inhibitory antibody of direct TF-VIIa signaling not only blocks TF-VIIa mediated activation of PAR2, but also disrupts the interaction of TF with integrins. In epithelial and TF-expressing endothelial cells, association of TF with beta1 integrins is regulated by TF extracellular ligand binding and independent of PAR2 signaling or proteolytic activity of VIIa. In contrast, alpha3beta1 integrin association of TF is constitutive in breast cancer cells and blocked by Mab-10H10 but not by Mab-5G9. Mab-5G9 has antitumor activity in vivo, but we show here that Mab-10H10 is at least as effective in suppressing human xenograft tumors in 2 different models. Breast tumor growth was also attenuated by blocking PAR2 signaling. These results show that tumor cell TF-PAR2 signaling is crucial for tumor growth and suggest that anti-TF strategies can be applied in cancer therapy with minor impairment of TF-dependent hemostatic pathways.

subject areas

  • Animals
  • Antibodies, Monoclonal
  • Antigens, CD29
  • Breast Neoplasms
  • Cell Division
  • Cell Line, Transformed
  • Endothelium, Vascular
  • Factor VIIa
  • Humans
  • Keratinocytes
  • Mice
  • Mice, SCID
  • Receptor, PAR-1
  • Receptor, PAR-2
  • Signal Transduction
  • Thromboplastin
  • Umbilical Veins
scroll to property group menus

Identity

PubMed Central ID

  • PMC2200804

International Standard Serial Number (ISSN)

  • 0006-4971

Digital Object Identifier (DOI)

  • 10.1182/blood-2007-07-101048

PubMed ID

  • 17901245
scroll to property group menus

Additional Document Info

start page

  • 190

end page

  • 199

volume

  • 111

issue

  • 1

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support